Price (delayed)
$26.31
Market cap
$7.5B
P/E Ratio
22.49
Dividend/share
N/A
EPS
$1.17
Enterprise value
$7.5B
Founded in 1994, Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work
There are no recent dividends present for EXEL.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.